Cargando…

The Effect of Prucalopride on the Completion Rate and Polyp Detection Rate of Colon Capsule Endoscopies

PURPOSE: To investigate whether the prokinetic prucalopride increases the completion rate of colon capsule endoscopy (CCE). Secondary outcomes included demographic distribution, polyp detection rate (PDR), distribution of Leighton–Rex grade, and adverse events. PATIENTS AND METHODS: In a nested coho...

Descripción completa

Detalles Bibliográficos
Autores principales: Deding, Ulrik, Kaalby, Lasse, Baatrup, Gunnar, Kobaek-Larsen, Morten, Thygesen, Marianne Kirstine, Epstein, Owen, Bjørsum-Meyer, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985819/
https://www.ncbi.nlm.nih.gov/pubmed/35401015
http://dx.doi.org/10.2147/CLEP.S353527
_version_ 1784682424492359680
author Deding, Ulrik
Kaalby, Lasse
Baatrup, Gunnar
Kobaek-Larsen, Morten
Thygesen, Marianne Kirstine
Epstein, Owen
Bjørsum-Meyer, Thomas
author_facet Deding, Ulrik
Kaalby, Lasse
Baatrup, Gunnar
Kobaek-Larsen, Morten
Thygesen, Marianne Kirstine
Epstein, Owen
Bjørsum-Meyer, Thomas
author_sort Deding, Ulrik
collection PubMed
description PURPOSE: To investigate whether the prokinetic prucalopride increases the completion rate of colon capsule endoscopy (CCE). Secondary outcomes included demographic distribution, polyp detection rate (PDR), distribution of Leighton–Rex grade, and adverse events. PATIENTS AND METHODS: In a nested cohort within the CareForColon2015 trial, a subgroup of 406 individuals underwent CCE in 2021. The first half (control) received the standard bowel preparation and the second half (prucalopride) was supplemented with 2 mg of prucalopride. Transit times and bowel preparations were analyzed and completion rates calculated as those having timely transit and acceptable bowel cleanliness. Major adverse events were recorded continuously and minor adverse events were quantified from questionnaires. RESULTS: The group demographics were homogenous. The prevalence ratio for complete CCE was 1.32 (CI 95% 1.15; 1.53) in the prucalopride group compared to the control group. Completion rate was 74.9% in the prucalopride group and 56.7% in the control group. The proportions of acceptable bowel preparation and complete transits were higher in the prucalopride group. The mean CCE transit time was 2 hours and 8 minutes faster in the prucalopride group. The PDR was higher in the intervention group with 55.7% compared to 36.0% in the control group for polyps greater than 9 mm, whereas the groups’ PDRs were similar for small and diminutive polyps. In all, 589 polyps (mean 2.9) were found in the prucalopride group compared to 522 polyps (mean 2.6) in the control group. CONCLUSION: Prucalopride led to an increase in CCE completion rates. The proportions of complete transits and acceptable bowel preparations were higher in the prucalopride group. The PDR was higher in the prucalopride group compared to the control group. No major adverse events were identified. Nausea, diarrhea, headache and fatigue were more commonly reported in the prucalopride group.
format Online
Article
Text
id pubmed-8985819
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-89858192022-04-07 The Effect of Prucalopride on the Completion Rate and Polyp Detection Rate of Colon Capsule Endoscopies Deding, Ulrik Kaalby, Lasse Baatrup, Gunnar Kobaek-Larsen, Morten Thygesen, Marianne Kirstine Epstein, Owen Bjørsum-Meyer, Thomas Clin Epidemiol Original Research PURPOSE: To investigate whether the prokinetic prucalopride increases the completion rate of colon capsule endoscopy (CCE). Secondary outcomes included demographic distribution, polyp detection rate (PDR), distribution of Leighton–Rex grade, and adverse events. PATIENTS AND METHODS: In a nested cohort within the CareForColon2015 trial, a subgroup of 406 individuals underwent CCE in 2021. The first half (control) received the standard bowel preparation and the second half (prucalopride) was supplemented with 2 mg of prucalopride. Transit times and bowel preparations were analyzed and completion rates calculated as those having timely transit and acceptable bowel cleanliness. Major adverse events were recorded continuously and minor adverse events were quantified from questionnaires. RESULTS: The group demographics were homogenous. The prevalence ratio for complete CCE was 1.32 (CI 95% 1.15; 1.53) in the prucalopride group compared to the control group. Completion rate was 74.9% in the prucalopride group and 56.7% in the control group. The proportions of acceptable bowel preparation and complete transits were higher in the prucalopride group. The mean CCE transit time was 2 hours and 8 minutes faster in the prucalopride group. The PDR was higher in the intervention group with 55.7% compared to 36.0% in the control group for polyps greater than 9 mm, whereas the groups’ PDRs were similar for small and diminutive polyps. In all, 589 polyps (mean 2.9) were found in the prucalopride group compared to 522 polyps (mean 2.6) in the control group. CONCLUSION: Prucalopride led to an increase in CCE completion rates. The proportions of complete transits and acceptable bowel preparations were higher in the prucalopride group. The PDR was higher in the prucalopride group compared to the control group. No major adverse events were identified. Nausea, diarrhea, headache and fatigue were more commonly reported in the prucalopride group. Dove 2022-04-02 /pmc/articles/PMC8985819/ /pubmed/35401015 http://dx.doi.org/10.2147/CLEP.S353527 Text en © 2022 Deding et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Deding, Ulrik
Kaalby, Lasse
Baatrup, Gunnar
Kobaek-Larsen, Morten
Thygesen, Marianne Kirstine
Epstein, Owen
Bjørsum-Meyer, Thomas
The Effect of Prucalopride on the Completion Rate and Polyp Detection Rate of Colon Capsule Endoscopies
title The Effect of Prucalopride on the Completion Rate and Polyp Detection Rate of Colon Capsule Endoscopies
title_full The Effect of Prucalopride on the Completion Rate and Polyp Detection Rate of Colon Capsule Endoscopies
title_fullStr The Effect of Prucalopride on the Completion Rate and Polyp Detection Rate of Colon Capsule Endoscopies
title_full_unstemmed The Effect of Prucalopride on the Completion Rate and Polyp Detection Rate of Colon Capsule Endoscopies
title_short The Effect of Prucalopride on the Completion Rate and Polyp Detection Rate of Colon Capsule Endoscopies
title_sort effect of prucalopride on the completion rate and polyp detection rate of colon capsule endoscopies
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985819/
https://www.ncbi.nlm.nih.gov/pubmed/35401015
http://dx.doi.org/10.2147/CLEP.S353527
work_keys_str_mv AT dedingulrik theeffectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies
AT kaalbylasse theeffectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies
AT baatrupgunnar theeffectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies
AT kobaeklarsenmorten theeffectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies
AT thygesenmariannekirstine theeffectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies
AT epsteinowen theeffectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies
AT bjørsummeyerthomas theeffectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies
AT dedingulrik effectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies
AT kaalbylasse effectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies
AT baatrupgunnar effectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies
AT kobaeklarsenmorten effectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies
AT thygesenmariannekirstine effectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies
AT epsteinowen effectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies
AT bjørsummeyerthomas effectofprucaloprideonthecompletionrateandpolypdetectionrateofcoloncapsuleendoscopies